Esperance Pharmaceuticals, Inc. is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. This start-up company is based on technology jointly developed at LSU, Pennington Biomedical Research Center, and LSU AgCenter.
VeroScience, LLC is committed to developing novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research. CyclosetTM was approved by the FDA in 2009 and is currently being sold by prescription as a stand-alone or add-on treatment for Type-2 diabetes in adults.
New Oil Resources, LLC was founded in 2008 by an LSU faculty member to commercialize a novel method for converting biomass into fuel. The company is currently optimizing its process and pursuing external funding and commercial partners.